A Trial Evaluating Stereotactic Radiotherapy Plus Durvalumab Continuation for Patients With NSCLC Metachronous Oligometastatic Disease Under Durvalumab Consolidation Following Chemoradiation

NCT03955198 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
4
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Institut Claudius Regaud